Regeneron Stock Soars 13%, Adding $11 Billion In Value As Sanofi Payments Surge

Shares hit a 52-week high after quarterly revenue rose 36.3% and executives called a new liver drug "game-changing."

Share
Regeneron Stock Soars 13%, Adding $11 Billion In Value As Sanofi Payments Surge

Regeneron Pharmaceuticals shares climbed 13.10% to $926.03 in Friday trading, as of 9:55 a.m. ET, adding $11 billion in market value and hitting a new 52-week high. The move came after third-quarter results showed Sanofi collaboration revenue jumping 68%.

Sanofi money drives the quarter

Adjusted earnings came in at $20.07 per share on revenue of $5.1 billion, up 36.3% from a year earlier, the company reported. Net income for the quarter ended September 30 was $1.9 billion.

The quarterly filing also showed a higher 2026 research budget and lower sales-cost guidance. Sanofi records global sales of Dupixent, the allergy and inflammation drug it shares with Regeneron, according to the company's annual report.

The stock was on pace for its biggest one-day gain in at least 275 trading sessions, since Sept. 26, 2025.

A liver drug called game-changing

On the earnings call, executives described a new liver-disease drug as "game-changing" but held back details. They said they will discuss it at an investor roundtable on November 10.

Regeneron is a biotechnology company that develops, makes and sells medicines for serious diseases. Its marketed products include Eylea HD and Eylea for eye disease, Libtayo for cancer and Praluent for cholesterol-related conditions.

A laggard turns leader

Before the jump, the stock was up about 6% year to date as of Thursday's close, trailing the S&P 500, which was up about 13% over the same span. Friday's surge lifts it to a fresh 52-week high.

The next date that matters is the November 10 roundtable, where Regeneron executives said they would detail the liver drug.

Sources

More on Regeneron Pharmaceuticals

All Regeneron Pharmaceuticals (REGN) coverage →